TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01845831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Bolus
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Study: NCT02491047

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC) treatment
Description: Standard of Care (SOC) treatment only
Study: NCT01845831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Sitagliptin
Description: Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
Study: NCT03577834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: liquid vinegar
Description: 6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vinegar pill
Description: Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
Study: NCT01108328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PolyGlycopleX (PGX)
Description: powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
Study: NCT01244035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
Study: NCT01292122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT-01
Description: Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
Study: NCT03032419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV-Al SSI
Description: 3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV SSI
Description: 3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
Study: NCT00330304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: isoniazid 10mg/kg orally, daily, for study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: Cotrimoxazole given 3 times a week or daily, orally, for study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cotrimoxazole
Description: Cotrimoxazole given 3 times a week or daily, orally, for study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: Isoniazid, 10mg/kg daily for study period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet identicle in appearance to intervention: isoniazid table
Study: NCT00594607

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69ST dialysis membrane
Description: AN69ST is the filter that the blood goes through during hemodialysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fx8 (Fresenius)
Description: Polysulphone dialysis membrane
Study: NCT01542463

Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed at the discretion of the physician
Study: NCT01047917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation DVD
Description: Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
Study: NCT01486355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Edmonston-Zagreb measles vaccine
Study: NCT05147753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: 0.6 mg moxonidine daily
Study: NCT03275090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoflipid ®
Study: NCT00855777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: etoricoxib 120 mg/day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: ibuprofen 1,800 mg/day for 3 days
Study: NCT03389698

Intervention type: DEVICE
Intervention: GRASP Dynamic Contrast-Enhanced (DCE) MRI
Description: Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.

Intervention type: DEVICE
Intervention: GRASP Dynamic Contrast-Enhanced (DCE) MRI
Description: Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.

Intervention type: DEVICE
Intervention: GRASP Dynamic Contrast-Enhanced (DCE) MRI
Description: Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.

Intervention type: DEVICE
Intervention: 3T Brain Scan
Description: Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.

Intervention type: DEVICE
Intervention: 3T Brain Scan
Description: Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.

Intervention type: DEVICE
Intervention: 3T Brain Scan
Description: Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.

Intervention type: DRUG
Intervention: Gadolinium-based Contrast Agent (GBCA) for MRI
Description: Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.

Intervention type: DRUG
Intervention: Gadolinium-based Contrast Agent (GBCA) for MRI
Description: Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.

Intervention type: DRUG
Intervention: Gadolinium-based Contrast Agent (GBCA) for MRI
Description: Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
Study: NCT01160393

Intervention type: DEVICE
Group type: OTHER
Intervention: Miniaturized bypass system
Description: Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
Study: NCT03180580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEAL guideline and healthy tiffin box intervention
Description: Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children.
Study: NCT04648917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeic acid
Description: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeic acid
Description: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
Study: NCT01110226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KML-001
Description: KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
Study: NCT00555282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter
Description: coated central venous catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheter
Description: standard central venous catheter
Study: NCT00602771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT04340921

Intervention type: BIOLOGICAL
Intervention: COVID-19 exposure
Description: Observation only

Intervention type: BIOLOGICAL
Intervention: COVID-19 exposure
Description: Observation only
Study: NCT00602771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally
Study: NCT03991182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMAGs trained on ECD curriculum
Description: 50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head women trained on ECD curriculum
Description: Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Head women led parent groups
Description: Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care of children 0-5 months
Description: The traditional care and education of caregivers/parents for children 0-5 months
Study: NCT00750178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat (MK0683 )
Description: Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days
Study: NCT00807014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duac Gel
Description: Duac® Gel will be applied to the face once daily at night, for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin gel
Description: Differin Gel will be applied to the face once daily at night, for 12 weeks.
Study: NCT03418064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fanfilcon A toric lens
Description: Contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B toric lens
Description: Contact lens
Study: NCT02052141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE 500
Description: 500 Units of CINRYZE administered by IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE 500
Description: 500 Units of CINRYZE administered by IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE 1000
Description: 1000 Units of CINRYZE administered by IV injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE 1000
Description: 1000 Units of CINRYZE administered by IV injection
Study: NCT00594087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: eszopiclone 2mg or 3mg at bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 mg or 3 mg at bedtime
Study: NCT02901340

Intervention type: DIETARY_SUPPLEMENT
Intervention: one to two liters of water daily
Study: NCT01961089

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galilei Lens Professional
Description: Measurement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galilei Lens Professional
Description: Measurement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galilei Lens Professional
Description: Measurement device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOLMaster
Description: Measurement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOLMaster
Description: Measurement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOLMaster
Description: Measurement device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenstar
Description: Measurement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lenstar
Description: Measurement device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lenstar
Description: Measurement device
Study: NCT02314871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: see Arm/group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramide
Description: see Arm/group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: see Arm/group description
Study: NCT03447119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well with a Disability
Description: Implementation of an adapted health promotion program.
Study: NCT02583997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing of lower alveoli
Description: After extraction of wisdom teeth, the lower alveoli are sutured closed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non suturing of lower alveoli
Description: After extraction of wisdom teeth, no alveoli are sutured closed.
Study: NCT00890669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking training with additional body load
Description: The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle.
Study: NCT02565446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resolution Elastography (MRE)
Description: Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resolution Elastography (MRE)
Description: Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
Study: NCT00845507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Sterile solution in equivalent doses as Exenatide
Study: NCT00953225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 4,000 IU daily for one year
Study: NCT01845831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Sitagliptin
Description: Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day.
Study: NCT00953225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo daily for one year
Description: Placebo
Study: NCT01590667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Litramine
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)
Study: NCT00430885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam (IVIG)
Description: Intravenous immunoglobulin 0.4 g/kg given as infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octagam (IVIG)
Description: Intravenous immunoglobulin 0.4 g/kg given as infusion
Study: NCT03612947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine +magnesium sulphate
Description: Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine only
Description: Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
Study: NCT04340921

Intervention type: BIOLOGICAL
Intervention: COVID-19 exposure
Description: Observation only
Study: NCT02733926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adding of vegetation into the backyards of kindergarten
Description: Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
Study: NCT00369317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03277482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
Study: NCT03420664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis VACOped
Description: Orthosis for lower limb immobilisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below knee cast
Description: Below knee cast for lower limb immobilisation